Deals in Depth: June/July 2010
Front-runners for June alliances were J&J's $586 million respiratory deal with Orexo and Bayer Schering's cancer partnership with OncoMed valued at about $540 million. Leading the pack for biopharma M&A was Grifol's $3.4 billion bid (plus $600 million in debt) for privately owned Talecris. In financings, both biopharma and device companies were busy raising private money, bringing in over $1.3 billion in June and July (compared with only $157 million in public sales).
You may also be interested in...
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.